Resverlogix
Home
Corporate Profile
Overview
History
Mission and Values
Senior Management
Board of Directors
Clinical Advisory Board
Clinical Steering Committee
Product Development
Overview
Cardiovascular Disease
Atherosclerosis
ApoA-I
Technology Platform
NexVas™ Animation
NexVas™ Plaque Regression
Lead Drug RVX-208
Autoimmune Drug Development Program
NexVas™ Alzheimer's Disease
ReVas™ Program
Clinical Trials
Completed Clinical Trials
Product Pipeline
Glossary
Partnering
Overview
Opportunities
Investors
Overview
Stock Info
Investor Documents
Analyst Coverage
FAQs
Investor Contact
Media
Overview
Press Releases
Fact Sheets
Events
Image Library
Awards & Recognition
Media Contact
Careers
Overview
Benefits
Current Opportunities
Contact Us
Request to be contacted
Sitemap
Corporate Profile
Overview
History
Mission and Values
Senior Management
Board of Directors
Clinical Advisory Board
Clinical Steering Committee
Product Development
Overview
Cardiovascular Disease
Atherosclerosis
ApoA-I
Technology Platform
NexVas™ Animation
NexVas™ Plaque Regression
Lead Drug RVX-208
Autoimmune Drug Development Program
NexVas™ Alzheimer's Disease
ReVas™ Program
Clinical Trials
Completed Clinical Trials
Product Pipeline
Glossary
Partnering
Overview
Opportunities
Investors
Overview
Stock Info
Investor Documents
Analyst Coverage
FAQs
Investor Contact
Media
Overview
Press Releases
Fact Sheets
Events
Image Library
Awards & Recognition
Media Contact
Careers
Overview
Benefits
Current Opportunities
Contact Us
Request to be contacted
Tweet
Page Tools
Related Links
FAQs
Press Releases
Glossary
Stock Quote
TSX:RVX
Price:
1.65
Change:
0.11
NEXVAS™ Animation
NexVas™ Animation
Annual Report
2011 Annual Report